News and Announcements
OncoSil US FDA Investigational Device Exemption Submitted
- Published December 14, 2015 12:32PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
14th December 2015, ASX Announcement
OncoSil Medical Lmited (ASX: OSL) (OncoSil Medical, the Company) is pleased to announce that it has filed an Investigational Device Exemption (IDE) with the US Food and Drug Administration (FDA) for its lead product candidate, the OncoSilTM localised radiation treatment for cancer.
This is a significant milestone in the development pathway for OncoSilTM in pancreatic cancer and is the firsts step towards securing FDA commercial approval for OncoSilTM under a Pre-market Appoval (PMA).
Subject to an IDE being granted, OncoSil Medical will commence a clinical study under the FDA to support the PMA. A PMA will allow the Company to commercially market OncoSilTM in the USA.
The company formally filed its IDE submission on 10th December 2015 after successfully completing a lengthy pre-IDE process. The pre-IDE process involved an FDA review of the proposed Clinical Investigational plan including the endorsement of clinical endpoints and outcomes measure.
To read the full announcement, please click here.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
